← All trials
NCT04754334
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 16, 2021
- Primary completion
- Aug 31, 2023
- Completion date
- Nov 30, 2023
- First posted
- Feb 15, 2021
- Last posted
- Jun 25, 2021
- Enrollment
- 450
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Oramed Pharmaceutical Inc.Lead sponsor
- Oramed Pharmaceutical Inc.Study chair
- IntegriumCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.